Eli Lilly sues four telehealth sites selling compounded Zepbound, Mounjaro
Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its diabetes drug Mounjaro.
Related Articles
Simon Schama: Trump’s war on knowledge
Attacks on Harvard and other universities are not just self-defeating — they are fundamentally un-American
Smart AI agents will radically change how we think about autonomization
Frontline AI from QuantumBlack, AI by McKinsey
Succinate-loaded tumor cell–derived microparticles reprogram tumor-associated macrophage metabolism
Engineered tumor cell–derived microparticles induce histone and enzyme succinylation in tumor-associated macrophages to promote an M1-like phenotype.
Advances in single-cell DNA sequencing enable insights into human somatic mosaicism
Nature Reviews Genetics – In this Review, Shao et al. discuss experimental and computational advances in single-cell DNA sequencing, insights into somatic genetic variation during…
Superprecise lasers show people a whole new color
By activating naturally impossible patterns of light-sensing cells, researchers showed five people the intense teal of “olo”
How Do Psychedelics Battle Stress? Scientists Find Their Influence Extends Beyond the Brain
The drugs disrupted communication between the brain and immune system to lower stress in mice.
Bioprinting Technique Brings Vascularized Tissue One Step Closer
Scientists can build microfluidic systems in a Petri dish out of collagen, cells, and other proteins with structural resolution and fidelity.
Reducing multitasking nurses’ workloads with ambient listening
According to Darren Batara, nursing innovation and informatics manager at Stanford Healthcare, ambient listening can help nurses balance documentation and patient care amid constant interruptions.
Signal Alert: Startup Seeks Community Funders for AAV Immuno-Gene Therapy
Siren said proceeds will go toward investigational new drug (IND)-enabling animal studies and clinical-grade production of therapy. Upon FDA approval of an IND application, Siren…